Skip to content

China Cord Blood Corp. in $65 Million Private Equity Investment by Growth Fund

Represented China Cord Blood Corp. (NYSE:CO), the first and largest cord blood-banking operator in China, in a $65 million private equity investment by funds affiliated with KKR China Growth Fund L.P., a China-focused investment fund managed by Kohlberg Kravis Roberts & Co., L.P. in April 2012. Loeb acted as company counsel in connection with the issuance of convertible debt to the investing fund, receipt of New York Stock Exchange listing approval and related issues and with the registration of the underlying ordinary shares with the US Securities and Exchange Commission.